SCHEMBL4862008

SCHEMBL4862008

CCOC(=O)C(C)(C)n1cnc(-c2cccnc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.54
CYP2E1 P05181 3/20 0.54
CYP2C9 P11712 3/20 0.54
CYP2B6 P20813 3/20 0.54
CYP2C19 P33261 3/20 0.54
CYP3A4 P08684 3/20 0.54
CYP2D6 P10635 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
DCTPP1 Q9H773 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
POLB P06746 2/20 0.42
LMNA P02545 1/20 0.42
MMP2 P08253 1/20 0.42
MMP13 P45452 1/20 0.42
MMP14 P50281 1/20 0.42
KDM4E B2RXH2 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870983 0.75 CYP2A6 (0.48) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL4869247 0.75 CYP2A6 (0.59) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL5507651 0.74 CYP2A6 (0.56) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL4864745 0.74 CYP2A6 (0.52) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL2690192 0.73 CYP2A6 (0.51) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL447273 0.72 CYP2A6 (0.50) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL12302883 0.72 CYP2A6 (0.60) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL27564026 0.72 MMP2 (0.48) MKNK1MKNK2DCTPP1POLBLMNA
SCHEMBL4870330 0.72 CYP2A6 (0.52) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19
SCHEMBL19941031 0.71 CYP2A6 (0.55) CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-20050009764-A1 Pyridyl substituted ketolide antibiotics CHIRON CORPORATION (US) 2005-01-13 US disclosed
US-6756359-B2 ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS CHIRON CORPORATION 2004-06-29 US disclosed
EP-1404693-A2 C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY CHIRON CORPORATION (US) 2004-04-07 EP disclosed
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity CHU DANIEL (US) 2003-07-03 US disclosed
WO-2003004509-A2 C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009764-A1 Pyridyl substituted ketolide antibiotics PKLR, KHK, PGD CYP2A6 57/4885CYP2E1 323/4885CYP2C9 10/4885
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity MRPL21, CYP51A1, CEL CYP2A6 68/4885CYP2E1 362/4885CYP2C9 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.